Prosidion Limited v Novo Nordisk (Corrected Version)

Link copied
Case Copied 18 min read

ABSTRACTS OF DECISIONS

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Application  :          No. 721477 in the name of PROSIDION LIMITED

Title:          Use of Dipeptidyl Peptidase IV Effectors for Lowering the Blood Glucose Level in Mammals

Action: Opposition by NOVO NORDISK under Section 104 of the Patents Act 1990

Decision:          Issued  28 February 2006          .

Abstract

The claims of the specification as accepted are in the Swiss-style, directed to the use of activity lowering effectors of Dipeptidyl Peptidase (DP IV), or of DP IV-like enzyme activity, for the preparation of a medicament for lowering elevated blood glucose levels.  The applicant sought to amend the specification to add claims to a method of lowering elevated blood glucose levels by the administration of a therapeutically effective amount of activity lowering effectors of Dipeptidyl Peptidase (DP IV), or of DP IV-like enzyme activity.

The opponent opposed the allowance of the amendments on the grounds that (i) the claims after amendments would not fall within the scope of the claims before amendment, and (ii) the amended claims would not satisfy the requirements of Section 40 because they would not be succinct.

After considering the European and New Zealand decisions relevant to interpreting Swiss-style claims the delegate concluded that in the Australian jurisdiction they should be construed consistently with accepted international practice i.e. these claims are directed to the manufacture of a medicament wherein the medicament is intended for a specified medical treatment, but do not extend to the method of medical treatment itself.

In relation to the present case, applying the “Distiller’s test” to this construction of the claims as accepted, the subject matter of proposed amended Claims 8 to 14 would not fall within the scope of accepted Claims 1 to 7 at acceptance because the latter do not encompass methods of treatment.  Consequently the proposed amendments are not allowable under Section 102(2)(a).

The opposition was successful and costs were awarded against the applicant.

PATENTS ACT 1990

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Re:Patent Application No. 721477 by PROSIDION LIMITED and Opposition thereto by NOVO NORDISK under Section 104 of the Patents Act 1990

BACKGROUND

15.  Patent 721477 was filed in the name of PROBIODRUG GESELLSCHAFT FUR ARZNEIMITTELFORSCHUNG MBH as PCT/DE/00820 under the Patent Cooperation Treaty on 24 April 1997 claiming priority from DE 97/19616486 dated 25 April 1996.   The application entered the National Phase in Australia on 30 October 1998 under application number 30233/97 and was advertised accepted on 6 July 2000.   A Notice of Opposition under Section 59 was filed on 5 October 2000.  The applicant subsequently changed its name to PROBIODRUG AG which was recorded on the application on 21 October 2002. 

16. The applicant filed a request to amend the patent under Section 104 on 9 December 2002. The opponent filed comments in relation to this request under Reg. 10.2(7) on 6 March 2003. The applicant responded to these comments on 10 April 2003 and the request was granted on 17 April…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Prosidion Limited v Novo Nordisk (Corrected Version) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2006] APO 6
Decision Date

CaseChat Overview and Summary

In Prosidion Limited v Novo Nordisk (Corrected Version), the dispute centred around the allowance of amendments to patent application No. 721477, originally filed by Prosidion Limited and opposed by Novo Nordisk under Section 104 of the Patents Act 1990. The original claims of the patent, as accepted, were in Swiss-style format, focusing on the use of Dipeptidyl Peptidase IV effectors for preparing a medicament to lower blood glucose levels. Prosidion sought to amend the specification to include method of treatment claims for lowering elevated blood glucose levels, which Novo Nordisk opposed on the grounds that the new claims would not fall within the scope of the original claims and would not comply with the succinctness requirements of Section 40. The Delegate of the Commissioner of Patents reviewed relevant European, British, and New Zealand decisions to determine the appropriate interpretation of Swiss-style claims in Australia, concluding that these claims should be construed consistently with international practice, meaning they are directed to the manufacture of a medicament intended for a specified medical treatment, but not the treatment method itself. The Delegate applied the "Distiller's test" and found that the proposed method of treatment claims would not fall within the scope of the accepted claims, thus they were not allowable under Section 102(2)(a). The opposition was successful, and costs were awarded against Prosidion.

The decision underscores the importance of claim construction in patent law, highlighting the need for consistency in interpreting claim forms across jurisdictions to provide clarity and certainty. The Delegate's conclusion that Swiss-style claims are not intended to extend to the method of medical treatment itself, but rather to the manufacture of a medicament for a specific use, aligns with broader international practices and aims to balance the protection of inventions with public policy considerations. This case reinforces the principle that amendments to a patent specification must not extend the scope of the original claims and must meet the requirements of clarity and succinctness under the Patents Act 1990.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.